Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Thyroid2012Vol. 23(5), pp. 600–604
Citations Over TimeTop 10% of 2012 papers
P. Savvides, Govardhanan Nagaiah, Pierre Lavertu, Pingfu Fu, James R. Wright, Robert Chapman, Jay Wasman, Afshin Dowlati, Scot C. Remick
Abstract
Sorafenib has activity in ATC, but at a low frequency and similar to our previous experience with fosbretabulin. One patient with a response had previously progressed on fosbretabulin. Toxicities were both predictable and manageable.
Related Papers
- → Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma(2011)272 cited
- → Comparison of Different Tumor Response Criteria in Patients with Hepatocellular Carcinoma After Systemic Therapy with the Multikinase Inhibitor Sorafenib(2010)29 cited
- → The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms(2018)9 cited
- → Potential synergistic effects of sorafenib and CP‑31398 for treating anaplastic thyroid cancer with p53 mutations(2020)8 cited
- [Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].(2011)